Skip to main content
Menu
search
0

Microfluidics-Enabled Antibody Discovery: Expediting Cancer and Immunology Research

case study icon

Microfluidics-Enabled Antibody Discovery: Expediting Cancer and Immunology Research

case study icon
Sphere Bio logo

Summary of Recent Advances in Microfluidic-Assisted Antibody Screening

Discover how Cyto-Mine® technology by Sphere Bio enhances antibody discovery with speed and precision. This 2021 study, published in mAbs, highlights how our microfluidics technology supports a “function first” screening approach of antibody-secreting cells, providing rapid identification of therapeutic candidates in just weeks.

Research highlights

  • Study Title: Versatile and Rapid Microfluidics-Assisted Antibody Discovery
  • Authors: Ramona Gaa, Emmanuel Menang-Ndi, Shruti Pratapa, Christine Nguyen, Satyendra Kumar, Achim Doerner
  • Published In: mAbs Journal, 2021
  • DOI: 10.1080/19420862.2021.1978130

Key findings

High Throughput and Precision: By using Cyto-Mine® technology, researchers screened up to two million droplets (1 million cells), identifying viable antibody-secreting cells with great efficiency with shortened timelines.
Functional Screening: This method supports functional IgG antibody screening, internalization and intracellular signaling, virus neutralization and the identification of cancer and immune disease antibodies with improved speed.
Antibody Development in Record Time: The Cyto-Mine® process—from cell preparation to antibody confirmation—was completed in four weeks, highlighting its ability to condense and streamline the antibody discovery process.

Additional Highlights

Streamlined Workflow: Microfluidics allows efficient screening for functionality in droplets, making Cyto-Mine® technology ideal for labs focusing on immune and cancer therapeutics.
Innovative Screening Capabilities: Researchers demonstrated functional antibody screening, which could support the development of therapeutic antibodies for diseases that are difficult to treat, including cancer and autoimmune diseases.

The Next Generation: Cyto-Mine® Chroma

Automate. Accelerate. Analyze millions of cells in a single day.

Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.

Cyto-Mine® Chroma
Contact sales